A randomized, controlled trial of replication-competent adenovirus-mediated suicide gene therapy [HSV thymidine kinase gene therapy] in combination with IMRT [intensity modulated radiotherapy]versus IMRT alone for the treatment of newly-diagnosed Prostate Cancer With an Intermediate Risk Profile.

Trial Profile

A randomized, controlled trial of replication-competent adenovirus-mediated suicide gene therapy [HSV thymidine kinase gene therapy] in combination with IMRT [intensity modulated radiotherapy]versus IMRT alone for the treatment of newly-diagnosed Prostate Cancer With an Intermediate Risk Profile.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Cytosine deaminase-herpes simplex virus-1 thymidine kinase fusion gene therapy (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ReCAP
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Mar 2016 Time frame for primary end point has been changed from 8 years to 5 years as reported by ClinicalTrials.gov record.
    • 08 May 2013 Interim results for the phase II part of the study presented at the 108th Annual Meeting of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top